Pure Global
NCT06363552

A Study of SC-0191 in Subjects With Metastatic Colorectal Cancer

A Study to Evaluate the Preliminary Safety and Efficacy of SC0191 as Single Agent or in Combination With Bevacizumab or 5-FU/LV in Advanced Colorectal Cancer
Tianshu Liu·Phase 2·ClinicalTrials.gov·drugNot yet recruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Metastatic Colorectal Cancer
Drug/Device/Intervention
SC0191
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Tianshu Liu
Funder
Shanghai Zhongshan Hospital
Location
Shanghai, China
Timeline & enrollment
Phase
Phase 2
Start date
May 01, 2024
End date
Dec 01, 2025
Enrollment
36 participants
Primary outcome

Objective Response Rate,Incidence and Severity of Dose Limiting Toxicities (DLTs)

Summary

The goal of this clinical trial is to evaluate the preliminary safety and efficacy of SC0191
 as single agent or in combination with bevacizumab or 5-FU/LV in advanced colorectal cancer.

ICD-10 classifications
Malignant neoplasm of colonMalignant neoplasm: Colon, unspecifiedMalignant neoplasm: Descending colonMalignant neoplasm: Ascending colonMalignant neoplasm: Overlapping lesion of colon
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06363552
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06363552 through Pure Global AI's free database. This Phase 2 trial is sponsored by Tianshu Liu and is currently Not yet recruiting. The study focuses on Metastatic Colorectal Cancer. Target enrollment is 36 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.